The randomized phaseII study about the skin hazard mitigation in the Erlotinib + oral steroid agent combined therapy and Erlotinib to non-small cell lung cancer patients

INTERVENTION: erlotinib 150mg/day prednisolone 10mg/ day 4weeks erlotinib 150mg/day CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: A two or more‐Grade skin adverse event rate SECONDARY OUTCOME: Adverse events; Skin adverse event rate and revelation time; A two or more‐Grade skin adverse event revelation time; Erlotinib administration rate ; QOL(EuroQol Group EQ‐5D‐3L) INCLUSION CRITERIA: 1.Histologically or cytological confirmed non‐small cell lung cancer 2. Age: 20years old or older 3. ECOG PS: 0‐2 4. Adequate organ function 5. Life expectancy more than 3 months 6. Written informed consent from the patient